Inhibition of the BCR-ABL TK depends on the drug concentration. In vitro studies have shown that leukemic cells respond to the treatment when the concentration of imatinib reaches 1 mM. However, clinical studies suggest that in vivo concentrations are not homogeneous throughout all tissues. Indeed, imatinib inhibition might be precluded by modifying the active drug concentration, thus accounting for the in vivo resistance observed in spite of the intermediate resistance demonstrated in vitro for the G250A mutation.
We have found a new mutation inducing intermediate resistance in response to dose escalation from a stable chronic phase disease and demonstrated in the cellular model. This 70-year-old woman is still alive in second chronic phase after more than 3 years of treatment. This case demonstrates that a small group of mutations inducing a very low level of resistance can be overcome with increasing doses of imatinib but without inducing any other mechanism of resistance. It also demonstrates that resistance level not only depends on the location of the amino acid but also on the type of substitution. Alanine has a chemical structure that is closer to the structure of glycine than to that of glutamic acid. It may be that the steric disturbance induced by alanine is lower than that induced by a glutamic acid. These amino acids located in the P-loop do not interact directly with the drug. Different amino acid substitutions at the same position leading to different levels of resistance have also been reported. 2 Corbin et al 6 also measured the IC 50 values of two mutations at T315 and found different levels of resistance for T315I and T315 V. This appears to be similar to the findings for G250E and G250A and undermines the tenet that different substitutions of T315 always lead to the same resistance level, as reported by other groups. 7 Results from previous studies have demonstrated that the T315I mutation is more resistant than G250E. 2, 8 In conclusion, this is the first report of intermediate resistance observed clinically, confirmed in vitro and correlated with slow clinical evolution in a CML patient. While the locations of mutations in the TK domain such as the P-loop are known to be important for the prognosis of the disease, this case shows that the type of mutation is also probably important for the evolution of CML under imatinib treatment.
Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation However, studies using conditional knock-in mice with PEBP2b-MYH11 have documented that while the fusion protein is critical for leukemogenesis, additional genetic events are required for the development of acute myeloblastic leukemia (AML). Recently, mutations in the class III receptor tyrosine kinase (RTK) including C-KIT and FLT3 were frequently found in patients with inv(16) AML.universally favorable. 1 In this study, we present a case of relapsed AML harboring inv(16) and a C-KIT exon 8 mutation who was successfully treated with imatinib and mild chemotherapy.
In total, 15 patients with inv(16) AML who gave informed consent in accordance with IRB were examined for the presence of mutations in the RTK genes. Mutations in the RTK genes were examined by reverse transcriptase-polymerase chain reaction and DNA sequencing, as previously described. 3, 4 Of 15 patients, three had mutations in the second tyrosine kinase domain (D816V), juxtamembrane domain (V556L) or exon 8 of the C-KIT gene. Another two patients showed FLT3-D835 mutations. We found no mutation in the N-Ras and K-Ras genes. A total of five (33%) patients had mutations in the RTK genes. It has also been shown that 69% of patients with inv(16) AML possess either a Ras or RTK mutation. 2 As well, a high prevalence of FLT3 mutations was observed in AML M0 patients with an AML1 mutation. 3 We also found RTK mutations in 18 of 37 (49%) patients with t(8;21) AML. 4 These observations lend support to the two-hit model for the pathogenesis of AML. 2 Our patient #33 showed an in-frame deletion plus insertion mutation in the C-KIT exon 8 ( Figure 1a ). Exon 8 mutations are highly associated with inv(16) AML and appear to adversely affect the relapse rate. 2 Most mutations involve codon D419, which locates near the fifth immunoglobulin-like extracellular domain. 2 The fourth domain plays a role in receptor dimerization, while the fifth is associated with proteolytic cleavage of the receptor and required for the structural integrity of receptors to bind stem cell factor (SCF). It is possible that mutations around D419 alter the conformation of these domains and lead to receptor activation or altered ligand affinity. Primary mononuclear cells from patient #33 were treated for 10 min at 371C with SCF (Kirin Brewery Co. Ltd., Tokyo, Japan), imatinib mesylate (Novartis Pharma AG, Basel, Switzerland), both compounds, or vehicle control in RPMI medium containing 10% FCS. Expression and phosphorylation of C-KIT were analyzed by Western blot using anti-C-KIT (Ab81: Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and antiphospho-C-KIT (Cell Signaling Technology, Beverly, MA, USA) antibodies. While no autophosphorylation of the C-KIT exon 8 mutant in primary AML cells was observed, SCF elicited a prominent increase in tyrosine phosphorylation of the C-KIT mutant (Figure 1b) . This is in line with a recent report that C-KIT exon 8 mutations caused hyperactivation of receptors in response to SCF and conferred IL-3 independent growth to Ba/F3 cells. 5, 6 Further, imatinib treatment of primary AML cells strongly downregulated phosphorylation of the C-KIT (Figure 1b) .
In March 2001, a 55-year-old man (patient #33) was diagnosed to have M4Eo with inv(16). He achieved complete remission (CR) with standard chemotherapy and received consolidation and maintenance according to the JALSG protocol. The first relapse was treated with high-dose cytarabine (HDAC) and mitoxantrone followed by a second CR. After four further courses of HDAC and one of anthracyclines, the patient received mild chemotherapy consisting of low-dose cytarabine and aclarubicin in combination with granulocyte colonystimulating factor (CAG) plus vincristine and prednisolone (VP) because he developed cardiac failure possibly due to the accumulation of anthracyclines. In March 2004, the patient presented with left inguinal granulocytic sarcomas with CD13 and CD34 antigens. His leukocyte count also evidenced the second relapse (Figure 2 ). HDAC combined with mitoxantrone and vindesine had no response. On the basis of Western blot analysis (Figure 1b) , he received imatinib at a dosage 400 mg/day combined with CAG plus VP therapy after giving written informed consent. After 2 weeks of treatment, the patient achieved a third hematological CR, although he failed to show a molecular CR (Figures 1a and 2) . Residual inguinal tumors regressed with radiation. Although two courses of this therapy were well tolerated, he did not receive further therapy because of the development of interstitial pneumonia possibly caused by imatinib. At 4 months later initiation of imatinib, he had a third relapse of AML.
A phase 2 study with 600 mg daily of imatinib was conducted in C-KIT-positive AMLs refractory to chemotherapy. 7 Of 21 patients without C-KIT mutation, responses were seen in five who presented relatively low blast counts in marrow and peripheral blood. However, imatinib monotherapy was discontinued because of disease progression in three t(8;21) or inv(16) AML patients with a C-KIT mutation. 8 Among these patients, two had the mutation at codon D816 that is refractory to imatinib in transfected cells. 6 Remaining one patient showed in-flame deletion plus insertion mutation in exon 8 of the C-KIT, in which imatinib therapy abrogated the leukemic subclone carrying the mutation although blasts in the peripheral blood and marrow rose quickly after treatment. 8 Therefore, the therapeutic benefits in patients with C-KIT exon 8 mutation appear to be achieved by combining imatinib with chemotherapy. In addition, in vitro simultaneous exposure to imatinib and other anticancer agents was found to produce synergistic or additive cytotoxic effects against Philadelphia chromosomepositive leukemias. Our case is the first to demonstrate that imatinib combined with mild chemotherapy induces a CR in a relapsed AML patient with C-KIT exon 8 mutation. Further studies will be necessary to confirm the efficacy of this approach for refractory AML. 
